Fundraising Fox

Philippe Dro

Investor

Partner at Adjuvant Capital

Germany

Writes $100K – $5M checks · typically $1.5M

About

Philippe Dro is trained in industrial pharmacy and finance and has worked across the European biotech and medtech sectors. His recent roles include Board member and CBO of Themis Biosciences (acquired by Merck & Co) and CEO and Supervisory Board member of GlycoVaxyn AG (acquired by GSK); earlier he served as CEO and Chairman of Endoart S.A. (acquired by Allergan) and was part of the founding team at Axovan (acquired by Actelion). His earlier pharmaceutical career included management positions at Novartis, SkyePharma, and Antares Pharma.

Contact· self-published, not guessed

Invests in

BiotechMedical Devices

Investments

Board seats

Luciole Medical AGScenic Biotech BV

Per the firm's website.

Colleagues at Adjuvant Capital

Frequently asked questions

Who is Philippe Dro?
Philippe Dro is trained in industrial pharmacy and finance and has worked across the European biotech and medtech sectors. His recent roles include Board member and CBO of Themis Biosciences (acquired by Merck & Co) and CEO and Supervisory Board member of GlycoVaxyn AG (acquired by GSK); earlier he served as CEO and Chairman of Endoart S.A. (acquired by Allergan) and was part of the founding team at Axovan (acquired by Actelion). His earlier pharmaceutical career included management positions at Novartis, SkyePharma, and Antares Pharma.
Where does Philippe Dro work?
Philippe Dro is Partner at Adjuvant Capital.
What does Philippe Dro invest in?
Philippe Dro invests in Biotech, Medical Devices.
What check size does Philippe Dro write?
Philippe Dro typically writes checks of $100K – $5M.
What boards does Philippe Dro sit on?
Philippe Dro holds tracked board seats at Luciole Medical AG, Scenic Biotech BV.